<DOC>
	<DOCNO>NCT02412787</DOCNO>
	<brief_summary>This extension study allow participant complete Study HGT-HIT-094 continue receive Elaprase treatment conjunction idursulfase IT continue receive Elaprase treatment begin concurrent IT treatment receive idursulfase IT treatment Study HGT-HIT-094 .</brief_summary>
	<brief_title>Long-Term Safety Clinical Outcomes Idursulfase IT Elaprase Treatment Pediatric Patients With Hunter Syndrome That Have Completed Study HGT-HIT-094</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Mucopolysaccharidosis II</mesh_term>
	<criteria>1 . Patients must complete Visit Week 52 assessment Study HGTHIT094 2 . The patient 's parent ( ) legally authorize guardian ( ) must voluntarily sign Institutional Review Board ( IRB ) /Independent Ethics Committee ( IEC ) approve informed consent form relevant aspect study explain discuss . Consent patient 's parent ( ) legally authorize guardian ( ) patient 's assent , relevant , must obtain 3 . The patient continue receive Elaprase regular basis Study HGTHIT094 1 . The patient experience , opinion Investigator , safety medical issue contraindicate treatment idursulfaseIT , include , limited , uncontrolled seizure disorder , bleed disorder , clinically relevant hypertension 2 . The patient know hypersensitivity component idursulfaseIT 3 . The patient clinically relevant intracranial hypertension 4 . The patient enrol another clinical study , HGTHIT094 , involve clinical investigation use investigational product ( drug [ intrathecal/spinal ] device ) within 30 day prior study enrollment time study 5 . The patient know suspected hypersensitivity anesthesia think unacceptably high risk anesthesia due compromise airways condition . 6 . The patient condition contraindicate described SOPHAPORT Mini S IDDD Instructions Use , include : 1 . The patient , may , allergic reaction material construction SOPHAPORT Mini S device 2 . The patient 's body size small support size SOPHAPORT Mini S Access Port , judge Investigator 3 . The patient 's drug therapy require substance know incompatible material construction 4 . The patient know suspect local general infection 5 . The patient risk abnormal bleeding due medical condition therapy 6 . The patient one spinal abnormality could complicate safe implantation fixation 7 . The patient function CSF shunt device 8 . The patient show intolerance implant device</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>